… agents have displayed modest efficacy. Vascular endothelial … I/II study we combined an
EGFR inhibitor, erlotinib, with an … to be halted for lack of efficacy. Otherwise an additional 24 …

… The efficacy and safety of bevacizumab in combination with first- or second-generation
EGFR-TKIs for the treatment of advanced EGFR-mutated NSCLC patients have been explored in …

… to bevacizumab treatment based on safety data. The non-comparative phase II BRAIN trial
(NCT00800202) is the first study to assess the efficacy/safety of bevacizumab in combination …

… We compared the efficacy and safety of bevacizumab and erlotinib … Our results were consistent
with NEJ026, where the combination of bevacizumab and erlotinib significantly prolonged …

… Only East Asian patients were recruited and analyzed in this study; whether this combination
has similar efficacy and toxicities in racial groups other than East Asians must be explored …

… We assessed whether the combination of erlotinib, an EGFR tyrosine kinase inhibitor,
with bevacizumab could increase the efficacy of maintenance therapy in patients with …

… these approaches, we evaluated in vivo the anti-tumour efficacy of the anti-angiogenic
compound bevacizumab, a highly specific monoclonal antibody directed against the vascular …

… efficacy and safety of a targeted therapeutic approach in which administration of bevacizumab
and erlotinib … Our results with the combination of bevacizumab/erlotinib are significantly …

… to improve efficacy and avoid the … of combined agents to erlotinib is difficult to detect in
erlotinib-sensitive tumor, we investigated the efficacy of erlotinib plus bevacizumab in erlotinib-…

… real-world efficacy, it is … , bevacizumab plus erlotinib might be considered among the first-line
therapeutic option in patients who cannot receive osimertinib and the strategy of combining …